Compare IDEXX Laboratories, Inc. (IDXX) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs iShares MBS ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while iShares MBS ETF trades at $89.79 (market cap $35.41B). The key difference: IDEXX Laboratories, Inc. and iShares MBS ETF are close in size by market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 5,388,525). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and iShares MBS ETF for 96 Days on average.
| IDXX | MBB | |
|---|---|---|
Market Cap | $40.43B | $35.41B |
Volume | 692,164 | 5,388,525 |
Sector | Health | Fixed Income |
52-Week High | $766.68 | $96.91 |
52-Week Low | $504.70 | $89.09 |
Typical Hold Time | 46 Days | 96 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding the $3.94 estimate. Revenue grew to $4.3 billion in 2025, and net income margin expanded to 25.03%. Recent acquisitions like CoVetAI aim to enhance veterinary workflow intelligence.
The outlook remains positive given robust profitability and analyst consensus, but risks include foreign exchange headwinds and competitive pressures. With a consensus price target of $665, representing ~30% upside, the stock offers growth potential for investors comfortable with its premium valuation multiples.
MBB, the iShares MBS ETF, trades at $89.73, up 0.57% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF recently hit a 52-week low amid rising short interest, which surged 98.3% in September 2026 (Defense World, 2026-09-29). Despite this, institutional investors like Corient Private Wealth and Baird Financial have increased their stakes, and Norway's sovereign wealth fund is rotating into mortgage-backed securities (ETF Trends, 2026-09-04).
The outlook for MBB is cautious due to interest rate sensitivity and convexity risks from its 5.68-year duration, with Seeking Alpha highlighting downside potential if the Fed hikes rates (2026-09-19). However, its high-quality MBS portfolio offers income appeal, with recent dividends paid. Risks include persistent inflation and prepayment volatility, but institutional accumulation suggests long-term confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
